Sign in
4

Changes in Ownership

NEKTAR THERAPEUTICS Filed Acc 0001209191-21-007942

SVP, COO & CFO sold 150,000 shares at an average $19.86 ($2,979,629)

  • SVP, COO & CFO acquired 150,000 shares (option exercise)

From the SEC's structured data for this filing

Trades in this filing

Labrucherie Gil M · SVP, COO & CFO

Table I: Non-derivative

9 lines
Date Transaction Shares Price Value Owned after D/I
2021-02-02 Exercise or conversion : show line 1 in the form +50,000 $8.80 $440,000 316,973 D
2021-02-02 Sale : show line 2 in the form −41,135 $19.97 $821,466 275,838 D
2021-02-02 Sale : show line 3 in the form −6,932 $20.96 $145,295 268,906 D
2021-02-02 Sale : show line 4 in the form −1,933 $21.66 $41,869 266,973 D
2021-02-03 Exercise or conversion : show line 5 in the form +25,000 $8.80 $220,000 291,973 D
2021-02-03 Exercise or conversion : show line 6 in the form +25,000 $8.80 $220,000 316,973 D
2021-02-03 Sale : show line 7 in the form −50,000 $19.61 $980,500 266,973 D
2021-02-04 Exercise or conversion : show line 8 in the form +50,000 $8.80 $440,000 316,973 D
2021-02-04 Sale : show line 9 in the form −50,000 $19.81 $990,500 266,973 D
Open-market sales · 150,000 sh · avg $19.86 · $2,979,629

Table II: Derivative

4 lines
Date Transaction Shares Owned after D/I
2021-02-02 Exercise or conversion : show line 10 in the form Stock Option −50,000 25,000 D
2021-02-03 Exercise or conversion : show line 11 in the form Stock Option −25,000 0 D
2021-02-03 Exercise or conversion : show line 12 in the form Stock Option −25,000 50,000 D
2021-02-04 Exercise or conversion : show line 13 in the form Stock Option −50,000 0 D
Loading xslF345X03/doc4.xml…